Search

Your search keyword '"Shen, Guo‐Liang"' showing total 30 results
Start Over Author "Shen, Guo‐Liang" Search Limiters Available in Library Collection
30 results on '"Shen, Guo‐Liang"'

4. Survival benefit from adjuvant TACE combined with Lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy

Author

Liang, Lei, primary, Xu, Zhu-Ding, additional, Lu, Wen-Feng, additional, Du, Cheng-Fei, additional, Gao, Zhen-Yu, additional, Huang, Xiao-Kun, additional, Wang, Kai-Di, additional, Ye, Tai-Wei, additional, Dai, Mu-Gen, additional, Liu, Si-Yu, additional, Shen, Guo-Liang, additional, Liu, Jun-Wei, additional, Zhang, Cheng-Wu, additional, and Huang, Dong-Sheng, additional

Published
2024
Full Text
View/download PDF

12. Impact of metabolic syndrome on the long-term prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy

Author

Zhang, Kang-Jun, primary, Ye, Tai-Wei, additional, Lu, Wen-Feng, additional, Xu, Fei-Qi, additional, Xie, Ya-Ming, additional, Wang, Dong-Dong, additional, Xiao, Zun-Qiang, additional, Liu, Si-Yu, additional, Yao, Wei-Feng, additional, Cheng, Jian, additional, Shen, Guo-Liang, additional, Liu, Jun-Wei, additional, Zhang, Cheng-Wu, additional, Huang, Dong-Sheng, additional, and Liang, Lei, additional

Published
2022
Full Text
View/download PDF

13. Association of preoperative albumin–bilirubin with surgical textbook outcomes following laparoscopic hepatectomy for hepatocellular carcinoma

Author

Xu, Fei-Qi, primary, Ye, Tai-Wei, additional, Wang, Dong-Dong, additional, Xie, Ya-Ming, additional, Zhang, Kang-Jun, additional, Cheng, Jian, additional, Xiao, Zun-Qiang, additional, Liu, Si-Yu, additional, Jiang, Kai, additional, Yao, Wei-Feng, additional, Shen, Guo-Liang, additional, Liu, Jun-Wei, additional, Zhang, Cheng-Wu, additional, Huang, Dong-Sheng, additional, and Liang, Lei, additional

Published
2022
Full Text
View/download PDF

29. Management of hepatocellular carcinoma rupture in the caudate lobe.

Author

Hong DF, Liu YB, Peng SY, Pang JZ, Wang ZF, Cheng J, Shen GL, and Zhang YB

Subjects
Adult, Blood Loss, Surgical, Carcinoma, Hepatocellular secondary, Chemoembolization, Therapeutic, Chemotherapy, Adjuvant, Disease Progression, Embolization, Therapeutic, Hepatectomy adverse effects, Humans, Liver Neoplasms pathology, Male, Middle Aged, Neoplasm Recurrence, Local, Operative Time, Reoperation, Retrospective Studies, Risk Factors, Rupture, Spontaneous, Survival Analysis, Time Factors, Time-to-Treatment, Treatment Outcome, Carcinoma, Hepatocellular surgery, Hepatectomy methods, Liver Neoplasms surgery
Abstract

Aim: To demonstrate that caudate lobectomy is a valid treatment in cases of hepatocellular carcinoma (HCC) rupture in the caudate lobe based on our experience with the largest case series reported to date., Methods: A retrospective study of eight patients presenting with spontaneous rupture and hemorrhage of HCC in the caudate lobe was conducted. Two patients underwent ineffective transarterial embolization preoperatively. Caudate lobectomy was performed in all eight patients. Bilateral approach was taken in seven cases for isolated complete caudate lobectomy. Left-sided approach was employed in one case for isolated partial caudate lobectomy. Transarterial chemoembolization was performed postoperatively in all patients., Results: Caudate lobectomy was successfully completed in all eight cases. The median time delay from the diagnosis to operation was 5 d (range: 0.25-9). Median operating time was 200 min (range: 120-310) with a median blood loss of 900 mL (range: 300-1500). Five patient remained in long-term follow-up, with one patient becoming lost to follow-up at 3 years and two patients currently alive at 7 and 19 mo. One patient required reoperation due to recurrence. Gamma knife intervention was performed for brain metastasis in another case. Two patients survived for 10 and 84 mo postoperatively, ultimately succumbing to multiple organ metastases., Conclusion: Caudate lobectomy is the salvage choice for HCC rupture in the caudate lobe. Local anatomy and physiologic features of the disease render caudate lobectomy a technically difficult operation. Postponement of surgical intervention is thus recommended while the rupture remains hemodynamically stable until an experienced surgeon becomes available. Prognosis is confounded by numerous factors, but long-term survival can be expected in the majority of cases.

Published
2015
Full Text
View/download PDF

30. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.

Author

Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, and Vitetta ES

Subjects
Animals, Antibodies, Monoclonal, Humanized, Antibody-Dependent Cell Cytotoxicity, Antigens, Surface immunology, Apoptosis physiology, Breast Neoplasms immunology, Breast Neoplasms pathology, Cell Division physiology, Complement Activation, Endothelial Growth Factors metabolism, Epitopes immunology, Female, Humans, In Vitro Techniques, Intercellular Signaling Peptides and Proteins metabolism, Lymphokines metabolism, Male, Mice, Mice, Inbred BALB C, Mice, Nude, Mice, SCID, Proto-Oncogene Mas, Receptor, ErbB-2 antagonists & inhibitors, Survival Rate, Trastuzumab, Tumor Cells, Cultured drug effects, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factors, Antibodies, Monoclonal therapeutic use, Breast Neoplasms therapy, Receptor, ErbB-2 immunology
Abstract

Her-2 (p185(erbB-2)) is a transmembrane tyrosine kinase receptor, which is encoded by the Her-2/neu proto-oncogene. Her-2 is overexpressed on 30% of highly malignant breast cancers. Monoclonal antibodies (MAbs) against Her-2 inhibit the growth of Her-2-overexpressing tumor cells and this occurs by a variety of mechanisms. One such MAb, Herceptin (Trastuzumab), has been approved for human use. We have generated a panel of murine anti-Her-2 MAbs against nine different epitopes on the extracellular domain of Her-2 and have evaluated the antitumor activity of three of these MAbs alone and in combination, both in vitro and in vivo. We found that MAbs (against different epitopes) make a highly effective mixture, which was more effective than the individual MAbs in treating s.c. tumor nodules of BT474 cells in SCID mice. In vitro, the MAb mixture was also more effective than the single MAbs in inducing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, inhibiting cell growth and inducing apoptosis, and inhibiting the secretion of vascular endothelial growth factor. Taken together, these activities might explain the superior performance of the MAb mixture in vivo.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results